Immunic (IMUX, Financial) has successfully finished enrolling participants for its phase 3 ENSURE trials, which are investigating the effectiveness of its primary asset, the nuclear receptor-related 1 activator called vidofludimus calcium. These trials focus on patients suffering from relapsing multiple sclerosis. Additionally, encouraging data has emerged from a phase 2 CALLIPER trial that involves patients with progressive multiple sclerosis, supporting the recent positive top-line results. This progress marks a significant step in Immunic's efforts to advance treatment options for multiple sclerosis.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Immunic Inc (IMUX, Financial) is $12.33 with a high estimate of $28.00 and a low estimate of $4.00. The average target implies an upside of 1,491.40% from the current price of $0.78. More detailed estimate data can be found on the Immunic Inc (IMUX) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Immunic Inc's (IMUX, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
